A medicinal plant compound, capnoidine, prevents the onset of inflammation in a mouse model of colitis

Shepherd, Catherine, Giacomin, Paul, Navarro, Severine, Miller, Catherine M., Loukas, Alex, and Wangchuk, Phurpa (2018) A medicinal plant compound, capnoidine, prevents the onset of inflammation in a mouse model of colitis. Journal of Ethnopharmacology, 211. pp. 17-28.

[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website: http://doi.org/10.1016/j.jep.2017.09.024


Ethnopharmacological relevance: The traditional uses of Corydalis dubia, Ajania nubigena and Pleurospermum amabile in the Bhutanese traditional medicine for treating disorders related to inflammatory conditions and the in vitro anti-inflammatory activity of their crude extracts inspired the isolation and the investigation of anticolitic properties of four pure compounds.

Materials and methods: Three medicinal plants were collected from Himalayan Mountains of Bhutan. Capnoidine and scoulerine were isolated from C. dubia, linalool oxide acetate from A. nubigena and isomyristicin from P. amabile using natural product isolation protocols. Four compounds were investigated for their anti-inflammatory activities against IBD-colitis using chemically induced (TNBS) mice model of colitis. Capnoidine conferred the best preliminary protection against TNBS-induced colitis in mice and we have conducted in-depth pharmacological investigation of this compound including clinical symptoms, pathological signs, cytokine profiles, histological structure and inflammasomes using relevant bioassay protocols.

Results: Capnoidine-treated mice had significantly: a) improved clinical symptoms (body weight loss, mobility, piloerection and faecal consistency); b) reduced colon pathology (adhesion, oedema, ulceration, and colon length); c) altered inflammatory cytokines profiles within the colons; d) reduced levels of p-IκB-α(Ser32) and p-NF-κB p65 (Ser536) and e) reduced histological inflammation in the colon when compared with mice administered TNBS only.

Conclusion: Capnoidine presents as a potential new anti-inflammatory drug lead candidate for diseases where current standard-of-care often fails and is associated with major side effects. It also validates the traditional uses of C. dubia against inflammatory conditions and underlines the value of pursuing bioactive compounds derived from traditionally used ethnobotanical medicines.

Item ID: 51040
Item Type: Article (Research - C1)
ISSN: 1872-8741
Funders: National Health and Medical Research Council of Australia (NHMRC)
Projects and Grants: NHMRC program grant APP1037304, NHMRC principle research fellowship APP1020114, NHMRC Peter Doherty Early Career Fellowship Grant APP1091011
Date Deposited: 05 Oct 2017 01:19
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3214 Pharmacology and pharmaceutical sciences > 321499 Pharmacology and pharmaceutical sciences not elsewhere classified @ 70%
32 BIOMEDICAL AND CLINICAL SCIENCES > 3202 Clinical sciences > 320211 Infectious diseases @ 30%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920109 Infectious Diseases @ 70%
92 HEALTH > 9202 Health and Support Services > 920299 Health and Support Services not elsewhere classified @ 30%
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page